Ketamine Assisted Psychotherapy

Search strategy:


AND

(DE "Ketamine" OR AB ketamine)

Databases: Medline, PsychINFO

Limits: 2015-2020, English language

Contents

Top Articles .................................................................................................................................................. 3

Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Ketamine with Psychotherapy ..................................................... 3

A Single Ketamine Infusion Combined With Motivational Enhancement Therapy for Alcohol Use Disorder: A Randomized Midazolam-Controlled Pilot Trial ................................................................. 3

d-Serine is a potential biomarker for clinical response in treatment of post-traumatic stress disorder using (R,S)-ketamine infusion and TIMBER psychotherapy: A pilot study. ......................................................... 3

Subanesthetic Dose Ketamine in Posttraumatic Stress Disorder: A Role for Reconsolidation During Trauma-Focused Psychotherapy? ........................................................................................................ 3

Toward specific ways to combine ketamine and psychotherapy in treating depression .......... 4

A proof-of-concept investigation into ketamine as a pharmacological treatment for alcohol dependence: study protocol for a randomised controlled trial ................................................................. 4

Intranasal Ketamine and Cognitive-Behavioral Therapy for Treatment-Refractory Obsessive-Compulsive Disorder .................................................................................................................................................. 4

Cognitive Behavior Therapy May Sustain Antidepressant Effects of Intravenous Ketamine in Treatment-Resistant Depression ........................................................................................................................................ 4

Treatment escalation in patients not responding to pharmacotherapy, psychotherapy, and electro-convulsive therapy: experiences from a novel regimen using intravenous S-ketamine as add-on therapy in treatment-resistant depression ............................................................................................. 4

Can exposure-based CBT extend the effects of intravenous ketamine in obsessive-compulsive disorder? an open-label trial ........................................................................................................................................... 5

PsychINFO ................................................................................................................................................. 6
<table>
<thead>
<tr>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Translating molecular and neuroendocrine findings in posttraumatic stress disorder and resilience to novel therapies</td>
<td>6</td>
</tr>
<tr>
<td>Exploring brain-derived neurotrophic factor Val66Met polymorphism and extinction learning-based treatment outcome in obsessive-compulsive disorder: A pilot study</td>
<td>6</td>
</tr>
<tr>
<td>Ketamine abuse potential and use disorder</td>
<td>6</td>
</tr>
<tr>
<td>Peak experiences and the afterglow phenomenon: When and how do therapeutic effects of hallucinogens depend on psychedelic experiences?</td>
<td>6</td>
</tr>
<tr>
<td>Medline</td>
<td>7</td>
</tr>
<tr>
<td>Reviewing the Potential of Psychedelics for the Treatment of PTSD.</td>
<td>7</td>
</tr>
<tr>
<td>Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments</td>
<td>7</td>
</tr>
<tr>
<td>Annual Research Review: Defining and treating pediatric treatment-resistant depression</td>
<td>7</td>
</tr>
<tr>
<td>Management of Treatment-Resistant Depression: Challenges and Strategies</td>
<td>7</td>
</tr>
<tr>
<td>The emergence of ketamine as a novel treatment for posttraumatic stress disorder</td>
<td>7</td>
</tr>
<tr>
<td>Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders</td>
<td>8</td>
</tr>
<tr>
<td>Searching for Treatments for Cocaine Use Disorder: The Quest Continues</td>
<td>8</td>
</tr>
<tr>
<td>Staging Treatment Intensity and Defining Resistant Depression: Historical Overview and Future Directions</td>
<td>8</td>
</tr>
<tr>
<td>Treatment for Substance Use Disorder With Co-Occurring Mental Illness</td>
<td>8</td>
</tr>
<tr>
<td>Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development</td>
<td>8</td>
</tr>
<tr>
<td>KETAMINE AS A POSSIBLE MODERATOR OF HYPNOTIZABILITY: A FEASIBILITY STUDY.</td>
<td>8</td>
</tr>
<tr>
<td>The Combination of Long-term Ketamine and Extinction Training Contributes to Fear Erasure by Bdnf Methylation</td>
<td>9</td>
</tr>
<tr>
<td>Ketamine-A Narrative Review of Its Uses in Medicine.</td>
<td>9</td>
</tr>
</tbody>
</table>
Top Articles

Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Ketamine with Psychotherapy.  
Academic Journal  
(English) By: Dore J; Turnipseed B; Dwyer S; Turnipseed A; Andries J; Ascani G; Monnette C; Huidekoper A; Strauss N; Wolfson P, Journal of psychoactive drugs [J Psychoactive Drugs], ISSN: 2159-9777, 2019 Apr-Jun; Vol. 51 (2), pp. 189-198; Publisher: Taylor & Francis; PMID: 30917760;  
Subjects: Hallucinogens administration & dosage; Ketamine administration & dosage; Psychotherapy methods; Adult: 19-44 years; All Adult: 19+ years; Female; Male

A Single Ketamine Infusion Combined With Motivational Enhancement Therapy for Alcohol Use Disorder: A Randomized Midazolam-Controlled Pilot Trial.  
Academic Journal  
(English) By: Dakwar E; Levin F; Hart CL; Basaraba C; Choi J; Pavlicova M; Nunes EV, The American journal of psychiatry [Am J Psychiatry], ISSN: 1535-7228, 2020 Feb 01; Vol. 177 (2), pp. 125-133; Publisher: American Psychiatric Association; PMID: 31786934;  
Subjects: Alcoholism therapy; Ketamine administration & dosage; Ketamine therapeutic use; Psychotherapy methods; Middle Aged: 45-64 years; All Adult: 19+ years; Female; Male

Academic Journal  
(English) By: Pradhan B; Mitrev L; Moaddell R; Wainer IW, Biochimica et biophysica acta. Proteins and proteomics [Biochim Biophys Acta Proteins Proteom], ISSN: 1570-9639, 2018 Jul; Vol. 1866 (7), pp. 831-839; Publisher: Elsevier; PMID: 29563072;  
Subjects: Ketamine therapeutic use; Mindfulness; Serine blood; Stress Disorders, Post-Traumatic therapy; Adult: 19-44 years; Middle Aged: 45-64 years; All Adult: 19+ years; Female; Male

Subanesthetic Dose Ketamine in Posttraumatic Stress Disorder: A Role for Reconsolidation During Trauma-Focused Psychotherapy?  
Academic Journal  
(English) By: Veen C; Jacobs G; Philippens I; Vermetten E, Current topics in behavioral neurosciences [Curr Top Behav Neurosci], ISSN: 1866-3370, 2018; Vol. 38, pp. 137-162; Publisher: Springer; PMID: 29637527;  
Subjects: Stress Disorders, Post-Traumatic
Toward specific ways to combine ketamine and psychotherapy in treating depression.
Academic Journal

(English) By: Hasler G, CNS spectrums [CNS Spectr], ISSN: 1092-8529, 2020 Jun; Vol. 25 (3), pp. 445-447; Publisher: Cambridge University Press; PMID: 31213212;

A proof-of-concept investigation into ketamine as a pharmacological treatment for alcohol dependence: study protocol for a randomised controlled trial.
Academic Journal

(English) By: McAndrew A; Lawn W; Stevens T; Porffy L; Brandner B; Morgan CJ, Trials [Trials], ISSN: 1745-6215, 2017 Apr 04; Vol. 18 (1), pp. 159; Publisher: BioMed Central; PMID: 28372596;

Intranasal Ketamine and Cognitive-Behavioral Therapy for Treatment-Refractory Obsessive-Compulsive Disorder.
Report

(English) By: Adams TG; Bloch MH; Pittenger C, Journal of clinical psychopharmacology [J Clin Psychopharmacol], ISSN: 1533-712X, 2017 Apr; Vol. 37 (2), pp. 269-271; Publisher: Williams And Wilkins; PMID: 28121735

Subjects: Antidepressive Agents pharmacology; Cognitive Behavioral Therapy methods; Depressive Disorder, Major therapy; Ketamine pharmacology; Obsessive-Compulsive Disorder therapy; Adult: 19-44 years; Young Adult: 19-24 years; All Adult: 19+ years; Male

Cognitive Behavior Therapy May Sustain Antidepressant Effects of Intravenous Ketamine in Treatment-Resistant Depression.
Academic Journal

(English) By: Wilkinson ST; Wright D; Fasula MK; Fenton L; Griepp M; Ostroff RB; Sanacora G, Psychotherapy and psychosomatics [Psychother Psychosom], ISSN: 1423-0348, 2017; Vol. 86 (3), pp. 162-167; Publisher: Karger; PMID: 28490030;

Subjects: Antidepressive Agents pharmacology; Cognitive Behavioral Therapy methods; Depressive Disorder, Major therapy; Depressive Disorder, Treatment-Resistant therapy; Ketamine pharmacology; Adult: 19-44 years; Middle Aged: 45-64 years; Young Adult: 19-24 years; All Adult: 19+ years; Female; Male

Treatment escalation in patients not responding to pharmacotherapy, psychotherapy, and electro-convulsive therapy: experiences from a novel regimen using intravenous S-ketamine as add-on therapy in treatment-resistant depression.
Academic Journal

(English) By: Kallmünzer B; Volbers B; Karthaus A; Tektas OY; Kornhuber J; Müller HH, Journal of neural transmission (Vienna, Austria : 1996) [J Neural Transm (Vienna)], ISSN: 1435-1463, 2016 May; Vol. 123 (5), pp. 549-52; Publisher: Springer-Verlag; PMID: 26721476;
Can exposure-based CBT extend the effects of intravenous ketamine in obsessive-compulsive disorder? an open-label trial.

Report

(English) By: Rodriguez CI; Wheaton M; Zwerling J; Steinman SA; Sonnenfeld D; Galfalvy H; Simpson HB, The Journal of clinical psychiatry [J Clin Psychiatry], ISSN: 1555-2101, 2016 Mar; Vol. 77 (3), pp. 408-9; Publisher: Physicians Postgraduate Press; PMID: 27046314

Subjects: Cognitive Behavioral Therapy methods; Implosive Therapy methods; Ketamine administration & dosage; Ketamine therapeutic use; Obsessive-Compulsive Disorder drug therapy; Obsessive-Compulsive Disorder therapy; Adolescent: 13-18 years; Adult: 19-44 years; Middle Aged: 45-64 years; Young Adult: 19-24 years; All Child: 0-18 years; All Adult: 19+ years
Translating molecular and neuroendocrine findings in posttraumatic stress disorder and resilience to novel therapies.
Academic Journal
DePierro, Jonathan; Lepow, Lauren; Feder, Adriana; Yehuda, Rachel; Biological Psychiatry, Vol 86(6), Sep 15, 2019 pp. 454-463. Publisher: Elsevier Science; [Journal Article] Subjects: Drug Therapy; Neurobiology; Posttraumatic Stress Disorder; Resilience (Psychological)

Academic Journal
Linkovski, Omer; Wheaton, Michael G.; Zwerling, Jordana; Odgerel, Zagaa; van Roessel, Peter; Filippou-Frye, Maria; Lombardi, Anthony; Wright, Brianna; Steinman, Shari A.; Simpson, Helen Blair; Lee, Francis; Rodriguez, Carolyn I.; Journal of Clinical Psychopharmacology, Vol 39(1), Jan-Feb, 2019 pp. 91-93. Publisher: Lippincott Williams & Wilkins; [Letter]
Subjects: Brief Psychotherapy; Cognitive Behavior Therapy; Ketamine; Polymorphism; Brain Derived Neurotrophic Factor; Adulthood (18 yrs & older)

Ketamine abuse potential and use disorder.
Academic Journal
Liu, Yu; Lin, Deyong; Wu, Boliang; Zhou, Wenhua; Brain Research Bulletin, Vol 126(Part 1), Sep, 2016 pp. 68-73. Publisher: Elsevier Science; [Journal Article]
Subjects: Antidepressant Drugs; Ketamine; Pharmacology

Peak experiences and the afterglow phenomenon: When and how do therapeutic effects of hallucinogens depend on psychedelic experiences?
Academic Journal
Subjects: Drug Abuse; Hallucinations; Ketamine; Obsessive Compulsive Disorder; Psychotherapy
Medline

Reviewing the Potential of Psychedelics for the Treatment of PTSD.
Academic Journal

(English) By: Krediet E; Bostoen T; Breeksema J; van Schagen A; Passie T; Vermetten E, The international journal of neuropsychopharmacology [Int J Neuropsychopharmacol], ISSN: 1469-5111, 2020 Jun 24; Vol. 23 (6), pp. 385-400; Publisher: Oxford University Press; PMID: 32170326;
© The Author(s) 2020. Published by Oxford University Press on behalf of CINP.

Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments.
Academic Journal

(English) By: Greenway KT; Garel N; Jerome L; Feduccia AA, Expert review of clinical pharmacology [Expert Rev Clin Pharmacol], ISSN: 1751-2441, 2020 Jun 01, pp. 1-15; Publisher: Taylor & Francis; PMID: 32478631;

Annual Research Review: Defining and treating pediatric treatment-resistant depression.
Academic Journal

(English) By: Dwyer JB; Stringaris A; Brent DA; Bloch MH, Journal of child psychology and psychiatry, and allied disciplines [J Child Psychol Psychiatry], ISSN: 1469-7610, 2020 Mar; Vol. 61 (3), pp. 312-332; Publisher: Blackwell Publishers; PMID: 32020643;

Management of Treatment-Resistant Depression: Challenges and Strategies.
Academic Journal

(English) By: Voineskos D; Daskalakis ZJ; Blumberger DM, Neuropsychiatric disease and treatment [Neuropsychiatr Dis Treat], ISSN: 1176-6328, 2020 Jan 21; Vol. 16, pp. 221-234; Publisher: Dove Medical Press; PMID: 32021216;

The emergence of ketamine as a novel treatment for posttraumatic stress disorder.
Academic Journal

(English) By: Feder A; Rutter SB; Schiller D; Charney DS, Advances in pharmacology (San Diego, Calif.) [Adv Pharmacol], ISSN: 1557-8925, 2020; Vol. 89, pp. 261-286; Publisher: Academic Press; PMID: 32616209;
© 2020 Elsevier Inc. All rights reserved.
Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders.
Academic Journal
(English) By: Sartori SB; Singewald N, Pharmacology & therapeutics [Pharmacol Ther], ISSN: 1879-016X, 2019 Dec; Vol. 204, pp. 107402; Publisher: Pergamon Press; PMID: 31470029;

Searching for Treatments for Cocaine Use Disorder: The Quest Continues.
Editorial & Opinion
(English) By: Brady KT, The American journal of psychiatry [Am J Psychiatry], ISSN: 1535-7228, 2019 Nov 01; Vol. 176 (11), pp. 892-893; Publisher: American Psychiatric Association; PMID: 31672040
Subjects: Cocaine; Cocaine-Related Disorders; Ketamine; Mindfulness; Substance-Related Disorders

Staging Treatment Intensity and Defining Resistant Depression: Historical Overview and Future Directions.
Academic Journal
(English) By: Salloum NC; Papakostas GI, The Journal of clinical psychiatry [J Clin Psychiatry], ISSN: 1555-2101, 2019 Jun 04; Vol. 80 (4); Publisher: Physicians Postgraduate Press; PMID: 31163105;
Subjects: Antidepressive Agents classification; Antidepressive Agents history; Antidepressive Agents pharmacology; Depressive Disorder, Treatment-Resistant diagnosis; Depressive Disorder, Treatment-Resistant drug therapy; Depressive Disorder, Treatment-Resistant history

Treatment for Substance Use Disorder With Co-Occurring Mental Illness.
Academic Journal
(English) By: Iqbal MN; Levin CJ; Levin FR, Focus (American Psychiatric Publishing) [Focus (Am Psychiatr Publ)], ISSN: 1541-4094, 2019 Apr; Vol. 17 (2), pp. 88-97; Publisher: American Psychiatric Pub; PMID: 31975963;

Academic Journal
(English) By: Schenberg EE, Frontiers in pharmacology [Front Pharmacol], ISSN: 1663-9812, 2018 Jul 05; Vol. 9, pp. 733; Publisher: Frontiers Media}; PMID: 30026698;

KETAMINE AS A POSSIBLE MODERATOR OF HYPNOTIZABILITY: A FEASIBILITY STUDY.
Academic Journal
The Combination of Long-term Ketamine and Extinction Training Contributes to Fear Erasure by Bdnf Methylation.

Academic Journal

(English) By: Ju LS; Yang JJ; Lei L; Xia JY; Luo D; Ji MH; Martynyuk AE; Yang JJ, Frontiers in cellular neuroscience [Front Cell Neurosci], ISSN: 1662-5102, 2017 Apr 20; Vol. 11, pp. 100; Publisher: Frontiers Research Foundation; PMID: 28473755;

Ketamine-A Narrative Review of Its Uses in Medicine.

Academic Journal

(English) By: Radvansky BM; Puri S; Sifonios AN; Eloy JD; Le V, American journal of therapeutics [Am J Ther], ISSN: 1536-3686, 2016 Nov/Dec; Vol. 23 (6), pp. e1414-e1426; Publisher: Lippincott Williams & Wilkins; PMID: 25923225;

Subjects: Excitatory Amino Acid Antagonists therapeutic use; Ketamine therapeutic use; Receptors, N-Methyl-D-Aspartate antagonists & inhibitors